{"preliminary_commentary":{"by_channel":{"x_thread":4,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["enfortumab vedotin","pembrolizumab"]],"indication":null,"name":"IMPROEV","nct_id":"NCT07221942","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=improev-nct07221942. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IMPROEV","arms":[{"description":"Participants will receive induction therapy with enfortumab vedotin (EV) plus pembrolizumab (P) for 6 cycles (approximately 18 weeks). EV will be administered at 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle (starting dose of 1 mg/kg allowed), and pembrolizumab at 200 mg IV on Day 1 of each cycle. Patients achieving complete or partial response will transition to maintenance pembrolizumab at 400 mg IV every 6 weeks or 200 mg IV every 3 weeks for up to 2 years. Dose modifications for EV are permitted per protocol; no dose adjustments for pembrolizumab. Treatment continues until disease progression, unacceptable toxicity, or completion of maintenance therapy.","label":"Induction EV + Pembrolizumab Followed by Maintenance Pembrolizumab","type":"EXPERIMENTAL"}],"collaborators":["United States Department of Defense"],"completion_date":{"date":"2029-09-03","type":"ESTIMATED"},"conditions":["Metastatic Urothelial Carcinoma","Unresectable Urothelial Carcinoma","Advanced Urothelial Carcinoma"],"enrollment":{"count":97,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Enfortumab vedotin","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-02-19","lead_sponsor":"Fox Chase Cancer Center","official_title":"Pembrolizumab Maintenance After Enfortumab Vedotin/Pembrolizumab Induction in Front-Line Metastatic Urothelial Carcinoma","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-09-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"18-month progression-free survival (PFS)","timeFrame":"18 months"}],"references":[],"start_date":{"date":"2026-01-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma","url":"https://clinicaltrials.gov/study/NCT07221942"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/improev-nct07221942"}